Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact

New Deal Could Be Worth Over $2.3bn

Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.

Money
Sanofi backs messenger RNA with bags of cash • Source: Shutterstock

Ahead of its closely watched R&D day, Sanofi has again expanded a pact with one of its key COVID-19 collaborators Translate Bio Inc. to develop messenger RNA (mRNA) vaccines across all infectious disease areas, making a hefty upfront payment to close the deal.

The two companies have been partners since 2018 when they signed a deal to develop mRNA vaccines for up to five infectious diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By 

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.